Former Bitcoin treasury
LIXTE Biotechnology Holdings, Inc. no longer pursues a Bitcoin treasury strategy. The holdings, debt, and metrics below reflect the last recorded data (Mar 31, 2026) and are no longer being updated.
₿$73,459.79▼ 0.12%
LIXTE Biotechnology Holdings, Inc.
LIXT🇺🇸Former
Clinical-stage biopharmaceutical company developing cancer therapies based on PP2A inhibitors. Adopted a corporate treasury policy in August 2025 to allocate up to 50% of treasury holdings to cryptocurrency, purchasing 10.5 BTC and 300 ETH with existing cash reserves.
BTC Holdings
0 BTC
Insufficient history
Stock PriceUpdated 11h ago
$6.25▲ 4.34%
180d
Total financing
0.00 USD
Insufficient history
mNAV
—
180d
Sats/Share
0
180d
Mkt cap
72.61M USD
Shares
11.62M
Fiat reserve
5.11M USD
Total reserve
5.11M USD
Dilution
0.0%
Analytics
FinancialsUnverified
US-GAAPAnnualAs of 2025-12-31
Balance Sheet
Total Assets$12.7M▲195.5%
Total Liabilities$1.8M
Stockholders' Equity$9.7M▲141.9%
Cash & Equivalents$5.1M▲21.5%
Total Debt—
Digital Assets$0
Income Statement
Revenue$0
Operating Income$-5.1M▼0.3%
Net Income$-6M▼18.1%
Interest Expense$9.2K▼43.6%
Cash Flow
Operating Cash Flow$-3.1M▲28.5%
Instruments
Recent Changes
Tue, Mar 31, 2026
Shares Outstanding
8.8M→11.6M+2.8M(+32.2%)
Form 10-K (2025)
Wed, Dec 31, 2025
BTC Holdings
10.5→0-10.5 BTC(-100.0%)
All 10.5925 BTC transferred for acquisition of Liora Technologies Europe Ltd.
Form 10-K (2025)Shares Outstanding
5.7M→8.8M+3.1M(+54.1%)
Form 10-K (2025)
Fiat Reserve
2.9M→5.1M+2.2M(+76.8%)USD
Form 10-K (2025)